Chemotherapy of brain turnour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles:: Revisiting the role of surfactants

被引:246
作者
Petri, B.
Bootz, A.
Khalansky, A.
Hekmatara, T.
Mueller, R.
Uhl, R.
Kreuter, J.
Gelperina, S.
机构
[1] Goethe Univ Frankfurt, Inst Pharmaceut Technol, D-60438 Frankfurt, Germany
[2] Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany
[3] Russian Acad Med Sci, Inst Human Morphol, Moscow, Russia
[4] Mundipharma Res GmbH & Co KG, D-65549 Limburg, Germany
[5] Res Ctr Mol Diagnost & Therapy, Moscow, Russia
关键词
apolipoprotein A-I; chemotherapy; glioblastoma; nanoparticles; poly(butyl cyanoacrylate); poloxamer; 188; polysorbate; 80; rats;
D O I
10.1016/j.jconrel.2006.10.015
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Poly(butyl cyanoacrylate) nanoparticles coated with poloxamer 188 (Pluronic (R) F68) and also, as shown previously, polysorbate 80 (Tween (R) 80) considerably enhance the anti-tumour effect of doxorubicin against an intracranial glioblastoma in rats. The investigation of plasma protein adsorption on the surface of the drug-loaded nanoparticles by two-dimensional electrophoresis (2-D PAGE) revealed that both surfactants, besides other plasma components, induced a considerable adsorption of apolipoprotein A-I (ApoA-I). It is hypothesized that delivery of doxorubicin to the brain by means of nanoparticles may be augmented by the interaction of apolipoprotein A-I that is anchored on the surface of the nanoparticles with the scavenger receptor class B type I (SR-BI) located at the blood-brain barrier. This is the first study that shows a correlation between the adsorption of apolipoprotein A-I on the nanoparticle surface and the delivery of the drug across the blood-brain barrier. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 31 条
[1]   Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro [J].
Alyaudtin, RN ;
Reichel, A ;
Löbenberg, R ;
Ramge, P ;
Kreuter, J ;
Begley, DJ .
JOURNAL OF DRUG TARGETING, 2001, 9 (03) :209-+
[2]   Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats [J].
Ambruosi, A ;
Yamamoto, H ;
Kreuter, J .
JOURNAL OF DRUG TARGETING, 2005, 13 (10) :535-542
[3]   Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats [J].
Ambruosi, A ;
Khalansky, AS ;
Yamamoto, H ;
Gelperina, SE ;
Begley, DJ ;
Kreuter, J .
JOURNAL OF DRUG TARGETING, 2006, 14 (02) :97-105
[4]   Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model [J].
Ambruosi, Alessandra ;
Gelperina, Svetlana ;
Khalansky, Alexander ;
Tanski, Sandra ;
Theisen, Alf ;
Kreuter, Joerg .
JOURNAL OF MICROENCAPSULATION, 2006, 23 (05) :582-592
[5]   Uptake and transport of high-density lipoprotein (HDL) and HDL-associated α-tocopherol by an in vitro blood-brain barrier model [J].
Balazs, Z ;
Panzenboeck, U ;
Hammer, A ;
Sovic, A ;
Quehenberger, O ;
Malle, E ;
Sattler, W .
JOURNAL OF NEUROCHEMISTRY, 2004, 89 (04) :939-950
[6]   COLLOIDAL CARRIERS FOR INTRAVENOUS DRUG TARGETING - PLASMA-PROTEIN ADSORPTION PATTERNS ON SURFACE-MODIFIED LATEX-PARTICLES EVALUATED BY 2-DIMENSIONAL POLYACRYLAMIDE-GEL ELECTROPHORESIS [J].
BLUNK, T ;
HOCHSTRASSER, DF ;
SANCHEZ, JC ;
MULLER, BW ;
MULLER, RH .
ELECTROPHORESIS, 1993, 14 (12) :1382-1387
[7]   Molecular weights of poly(butyl cyanoacrylate) nanoparticles determined by mass spectrometry and size exclusion chromatography [J].
Bootz, A ;
Russ, T ;
Gores, F ;
Karas, M ;
Kreuter, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2005, 60 (03) :391-399
[8]   Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles [J].
Bootz, A ;
Vogel, V ;
Schubert, D ;
Kreuter, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 57 (02) :369-375
[9]   Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model [J].
Brigger, I ;
Morizet, J ;
Laudani, L ;
Aubert, G ;
Appel, M ;
Velasco, V ;
Terrier-Lacombe, MJ ;
Desmaële, D ;
d'Angelo, J ;
Couvreur, P ;
Vassal, G .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :29-40
[10]   Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action [J].
deVerdiere, AC ;
Dubernet, C ;
Nemati, F ;
Soma, E ;
Appel, M ;
Ferte, J ;
Bernard, S ;
Puisieux, F ;
Couvreur, P .
BRITISH JOURNAL OF CANCER, 1997, 76 (02) :198-205